| Biomarker ID | 15 |
| PMID | 15067324 |
| Year | 2004 |
| Biomarker | MGC5466+CHAF1A+CDS2+IER3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed in Recurrent Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Recurrence Vs No Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 21 patients were divided into two subgroups representing prostate cancer with recur- rent (8 patients) and nonrecurrent (13 patients). Validation set consisted of 79 patients with 37 recurrent and 42 non recurrent) |
| Senstivity | Recurrent Cancer Prediction: 88% |
| Specificity | Non Recurrent Cancer Prediction: 92% |
| AUC | NA |
| Accuracy | 90% |
| Level Of Significance | p<0.0001 |
| Method Used | RNeasy or Fast-Tract kits |
| Clinical | No |
| Remarks | Results shown for Training Set |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NIPA2, CHAF1A, CDS2, IER3 |